Literature DB >> 15579801

A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk.

Irina U Agoulnik1, Xiao-Wen Tong, Dagmar-C Fischer, Klaus Körner, Neely E Atkinson, Dean P Edwards, Denis R Headon, Nancy L Weigel, Dirk G Kieback.   

Abstract

Recently, we and others have detected a haplotype of the human progesterone receptor gene (PR). This haplotype consists of a 320-bp insertion in intron G together with point mutations in exons 4 and 5 and was named PROGINS. Whereas the exon 5 mutation is silent, the mutation in exon 4 results in a V660L substitution. Interestingly, this genetic polymorphism was seen to cosegregate with an increased risk of sporadic ovarian cancer in different ethnic groups. Our data provide evidence for the existence of an epidemiological link between a mutated progesterone receptor allele and ovarian cancer (odds ratio, 3.02; 95% confidence interval, 1.86-4.91). Functional characterization of the mutated receptor protein revealed a greater transcriptional activity compared with the wild-type receptor. By contrast, hormone binding and hormone dissociation rates were similar in both receptor proteins. We found that the increased transcriptional activity was due to increased stability resulting in higher expression of the mutant protein. Thus, the long-lasting hyperactivation of progesterone receptor-driven genes secondary to the increased transcriptional activity of the mutated progesterone receptor may participate in ovarian carcinogenesis. This is of special interest, because only a few genetic markers are available for the majority of women diagnosed with sporadic ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15579801     DOI: 10.1210/jc.2004-0114

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  27 in total

1.  Dynamic regulation of Drosophila nuclear receptor activity in vivo.

Authors:  Laura Palanker; Aleksandar S Necakov; Heidi M Sampson; Ruoyu Ni; Chun Hu; Carl S Thummel; Henry M Krause
Journal:  Development       Date:  2006-08-16       Impact factor: 6.868

2.  Analyze association of the progesterone receptor gene polymorphism PROGINS with ovarian cancer risk.

Authors:  Cunzhong Yuan; Cunfang Wang; Xiaoyan Liu; Beihua Kong
Journal:  Mol Biol Rep       Date:  2013-09-21       Impact factor: 2.316

Review 3.  Genomics of preterm birth.

Authors:  Kayleigh A Swaggart; Mihaela Pavlicev; Louis J Muglia
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-02       Impact factor: 6.915

Review 4.  Genetics of menstrual migraine: the molecular evidence.

Authors:  Natalie Colson; Francesca Fernandez; Lyn Griffiths
Journal:  Curr Pain Headache Rep       Date:  2010-10

5.  Progesterone and Breast Cancer: an NCI Workshop Report.

Authors:  Neeraja Sathyamoorthy; Carol A Lange
Journal:  Horm Cancer       Date:  2020-02       Impact factor: 3.869

6.  Rapid estrogen-induced phosphorylation of the SRC-3 coactivator occurs in an extranuclear complex containing estrogen receptor.

Authors:  Fuzhong F Zheng; Ray-Chang Wu; Carolyn L Smith; Bert W O'Malley
Journal:  Mol Cell Biol       Date:  2005-09       Impact factor: 4.272

7.  Associations of progesterone receptor polymorphisms with age at menarche and menstrual cycle length.

Authors:  K C Taylor; C M Small; M P Epstein; S L Sherman; W Tang; M M Wilson; M Bouzyk; M Marcus
Journal:  Horm Res Paediatr       Date:  2010-09-02       Impact factor: 2.852

8.  Progesterone receptor PROGINS and +331G/A polymorphisms confer susceptibility to ovarian cancer: a meta-analysis based on 17 studies.

Authors:  Ting Liu; Lilan Chen; Xiangjun Sun; You Wang; Shu Li; Xia Yin; Xinran Wang; Chenhuan Ding; He Li; Wen Di
Journal:  Tumour Biol       Date:  2013-11-07

9.  Polymorphisms in genes involved in sex hormone metabolism, estrogen plus progestin hormone therapy use, and risk of postmenopausal breast cancer.

Authors:  Brenda Diergaarde; John D Potter; Eldon R Jupe; Sharmila Manjeshwar; Craig D Shimasaki; Thomas W Pugh; Daniele C Defreese; Bobby A Gramling; Ilonka Evans; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-07       Impact factor: 4.254

10.  Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity.

Authors:  I Barone; D Iacopetta; K R Covington; Y Cui; A Tsimelzon; A Beyer; S Andò; S A W Fuqua
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.